The 5000% case: a glimpse into the financial issue of lung cancer treatment

Remon Jordi, Bonastre Julia, Besse Benjamin

Source: Eur Respir J 2016; 47:1331-1333
Journal Issue: May

Full text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Remon Jordi, Bonastre Julia, Besse Benjamin. The 5000% case: a glimpse into the financial issue of lung cancer treatment. Eur Respir J 2016; 47:1331-1333

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
An abnormal CT, now what: issues in the diagnosis and management of a patient with a potential lung cancer
Source: Annual Congress 2006 - MP11 - An abnormal CT, now what: issues in the diagnosis and management of a patient with a potential lung cancer
Year: 2006

When lung cancer was rare: An historical study of prevalence from 1760 .
Source: International Congress 2018 – Lung cancer: risk factors, supportive measures and quality improvement
Year: 2018


A new WHO classification for lung cancer after 11 years: clinical implications
Source: International Congress 2015 – Lung cancer pathology
Year: 2015



A network lung cancer pathway in review: Are we choosing the right diagnostic approach?
Source: Annual Congress 2010 - Quality management for lung cancer patients
Year: 2010


Lung cancer survival in the UK: are the results from the national lung cancer audit (LUCADA) dependent on completeness of case reporting?
Source: Annual Congress 2009 - Epidemiology and management of lung cancer
Year: 2009


ERS School Course Early-stage lung cancer - What's new in the epidemiology of lung cancer: the female aspect
Source: ISSN=ISSN 1810-6838, ISBN=, page=339
Year: 2006

A study of the public‘s awareness of the causation of lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 184s
Year: 2005

Biomarkers for non-small cell lung cancer (NSCLC) treatment: examples and unmet needs, a clinical perspective
Source: International Congress 2014 – From bench to bedside: biomarkers and biobanking for lung cancer in 2014
Year: 2014



Lung cancer: the importance of seeing a respiratory physician
Source: Eur Respir J 2003; 21: 606-610
Year: 2003



COVID-19 and the management of thoracic cancer patients: challenges and recommendations
Source: ERS webinar 2020: COVID-19 and the management of thoracic cancer patients: challenges and recommendations
Year: 2020


Trends of the proportion of small-cell lung cancer (SCLC) over the last 20 year: a university medical center experience
Source: Annual Congress 2007 - Rare tumours, risk factors and epidemiology in thoracic oncology
Year: 2007


ESR/ERS statement paper on lung cancer screening
Source: Guideline 2020
Year: 2020

ESR/ERS statement paper on lung cancer screening
Source: Eur Respir J, 55 (2) 1900506; 10.1183/13993003.00506-2019
Year: 2020



The changing face of lung cancer: Evidence from a 14-year study
Source: Eur Respir J 2003; 22: Suppl. 45, 252s
Year: 2003

Treatment of extensive-stage small cell lung carcinoma: current status and future prospects
Source: Eur Respir J 2010; 35: 202-215
Year: 2010



Survival outcomes in advance non-small cell lung cancer – A developing country scenario
Source: Annual Congress 2011 - Quality management for lung cancer patients
Year: 2011

Gemcitabine (G) or vinorelbine (V)? What's the best drug in combination with a platinium-derivative for the treatment of locally advanced and metastatic non small cell lung cancer (NSCLC)? A 6 years retrospective study
Source: Eur Respir J 2003; 22: Suppl. 45, 527s
Year: 2003

Close surveillance strategy for early lung cancer: results of 15 years of observation
Source: Annual Congress 2008 - New trends in interventional pulmonology
Year: 2008